MEMPHASYS LIMITED. — Capital/Financing Update 2024

Nov 27, 2024

28 November 2024

==> picture [195 x 46] intentionally omitted <==

ASX Release

ASX Code: MEM

Extension of Convertible Note

Memphasys Limited (ASX: MEM) (Company) announces that it has executed an Amendment Deed to the Convertible Note Agreement (Note) between the Company and Peters Investments Pty Ltd whereby:

• a) the Note maturity date is extended from 31 December 2024 to 30 June 2025; and b) any interest accrued on the Convertible Notes from 1 January 2025 shall only be repayable in cash.

Execution of the Deed follows the announcement issued by the Compony on 12 September 2024 whereby Peters Investments Pty Ltd had agreed to extend the maturity date of the Notes (with an aggregate face value of $3m, plus capitalised facilitation fees and accrued interest) to 30 June 2025.

The Board expresses its thanks to Peters Investments Pty Ltd for the continued support it has shown the Company.

Approved for release by the Board.

ENDS

For further information, please contact:

Dr David Ali Managing Director & CEO Memphasys Limited Tel: +61 2 8415 7300 E: david.ali@memphasys.com>

About Memphasys

Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company’s patented bio separation technology, utilised by the Company’s most advanced product, the Felix™ System, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction. Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.

E info@memphasys.com W memphasys.com ABN 33 120 047 556

Contact Details P +612 8415 7300

Memphasys Limited Level1, 34-36 Richmond Road Homebush West, NSW 2140

– 2 –